Skip to Main Content

Author Details

Alan W Katz
University of Rochester
1996
76
34
PMIDPaper TitleJournal TitlePublished Year
34774650Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond.Radiother Oncol2022
35038433Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial.Lancet Oncol2022
34862242Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy.Clin Cancer Res2022
34400269Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.Int J Radiat Oncol Biol Phys2022
34836735Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis.Clin Oncol (R Coll Radiol)2022
33035622Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control.Radiother Oncol2021
33493615Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.Int J Radiat Oncol Biol Phys2021
33855816Dosimetric and clinical outcomes of SpaceOAR in men undergoing external beam radiation therapy for localized prostate cancer: A systematic review.J Med Imaging Radiat Oncol2021
34585025Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series.Adv Radiat Oncol2021
32663537Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.Radiother Oncol2020
31985516Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.Am J Clin Oncol2020
33391899Prostate Stereotactic Body Radiation Therapy With Halcyon 2.0: Treatment Plans Comparison Based on RTOG 0938 Protocol.Cureus2020
30873385Hypofractionated Stereotactic Radiotherapy for Non-breast or Prostate Cancer Oligometastases: A Tail of Survival Beyond 10 Years.Front Oncol2019
31762753Hypofractionated Stereotactic Radiation Therapy for Metastatic Adenocarcinoma ex Goblet Cell Carcinoid of the Appendix: Case Report and Literature Review.Case Rep Oncol2019
31179045Stereotactic body radiation therapy versus metastasectomy for oligometastases.J Thorac Dis2019
30773186Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade.Radiother Oncol2019
30735235Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.JAMA Netw Open2019
31032106Short course radiation therapy for rectal cancer in the elderly: can radical surgery be avoided?J Gastrointest Oncol2019
30825666NRG Oncology/RTOG 0438: A Phase 1 Trial of Highly Conformal Radiation Therapy for Liver Metastases.Pract Radiat Oncol2019
26270442Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer: Prognostic Factors for Disease Control and Survival.Am J Clin Oncol2018
28494653Patterns and Yearly Time Trends in the Use of Radiation Therapy During the Last 30 Days of Life Among Patients With Metastatic Rectal Cancer in the United States From 2004 to 2012.Am J Hosp Palliat Care2018
29664795Impact of Right-sided Primary Tumor Location Among Patients With Oligometastatic Colorectal Cancer Treated With Stereotactic Body Radiotherapy.Am J Clin Oncol2018
28710606SBRT for Hepatocellular Carcinoma: 8-Year Experience from a Regional Transplant Center.J Gastrointest Cancer2018
28821268Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.Radiat Oncol2017
29152425Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis.Cureus2017
27458572Predicting Biochemical Disease-Free Survival after Prostate Stereotactic Body Radiotherapy: Risk-Stratification and Patterns of Failure.Front Oncol2016
27867636Oligometastases to the liver: predicting outcomes based upon radiation sensitivity.J Thorac Dis2016
25222074Can Surgery be Avoided After Preoperative Chemoradiation for Rectal Cancer in the Era of Organ Preservation? Current Review of Literature.Am J Clin Oncol2015
28799575Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.Adv Radiat Oncol2015
26557080Long-Term Survival of a Patient with Metastatic Small-Cell Carcinoma of the Stomach Treated with Radiation Therapy.Case Rep Oncol2015
24382205Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.Radiat Oncol2014
25229051Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study.Front Oncol2014
25389521Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.Front Oncol2014
24581472Supraumbilical rash caused by nontarget radioembolization to the falciform artery.J Vasc Interv Radiol2014
24575010Stereotactic body radiation therapy as a bridge to transplantation and for recurrent disease in the transplanted liver of a patient with hepatocellular carcinoma.Case Rep Oncol2014
22278932Cyberknife radiosurgery in treating trigeminal neuralgia.J Neurointerv Surg2013
24119836Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.Int J Radiat Oncol Biol Phys2013
24060175Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.Radiother Oncol2013
23668632Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.Radiat Oncol2013
23745991Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients.Radiat Res2013
23458468Multicentre results of stereotactic body radiotherapy for secondary liver tumours.HPB (Oxford)2013
23233707Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.J Clin Oncol2013
21533812Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research.Support Care Cancer2012
23164305Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.Radiat Oncol2012
23275779Esophageal metastasis to the iris effectively palliated using stereotactic body radiation therapy and adjuvant intravitreal chemotherapy: case report and literature review.Case Rep Oncol2012
22263926Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors.Acta Oncol2012
22172906Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma: clinical outcome and pathologic correlation.Int J Radiat Oncol Biol Phys2012
22172903Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.Int J Radiat Oncol Biol Phys2012
20400244Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting.Int J Radiat Oncol Biol Phys2011
22655249Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?Front Oncol2011
  • 1 - 50 of 76

Recommended Authors

Western University and London Regional Cancer Program
Career Start Year 2013
Number of shared co-authors 2
Stanford University
Career Start Year 2012
Number of shared co-authors 8
Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 19
Rutgers Robert Wood Johnson Medical School, Rutgers University
Career Start Year 2011
Number of shared co-authors 9
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 10
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 3
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 20
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 2006
Number of shared co-authors 19
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 10
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 3
University of Texas Southwestern Medical Center
Career Start Year 2004
Number of shared co-authors 12
Ghent University, GZA Ziekenhuizen
Career Start Year 2002
Number of shared co-authors 13
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 3
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 24
William Beaumont School of Medicine
Career Start Year 1999
Number of shared co-authors 19
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 13
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 8
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Career Start Year 1996
Number of shared co-authors 4
Huntsman Cancer Institute, University of Utah
Career Start Year 1994
Number of shared co-authors 19
Western University and London Regional Cancer Program
Career Start Year 1994
Number of shared co-authors 3
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 25
Johns Hopkins University School of Medicine
Career Start Year 1991
Number of shared co-authors 23
Mayo Clinic
Career Start Year 1991
Number of shared co-authors 16
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 23
Sutter Cancer Centers Radiation Oncology Services
Career Start Year 1987
Number of shared co-authors 18
Mount Vernon Cancer Centre
Career Start Year 1985
Number of shared co-authors 12
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 20
Massachusetts General Hospital
Career Start Year 1982
Number of shared co-authors 2
Chester County Hospital
Career Start Year 1982
Number of shared co-authors 5
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 23

Collaborators

Vanderbilt University School of Medicine
Co-authored papers 9
University of California los angeles
Co-authored papers 8
Division of Genesis Healthcare Partners Inc., CyberKnife Centers of San Diego Inc.
Co-authored papers 8
University of Chicago
Co-authored papers 6
Beth Israel Deaconess Medical Center, Harvard Medical School
Co-authored papers 6
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 6
university of california los angeles Medical Center
Co-authored papers 6
University of California los angeles
Co-authored papers 6
Stanford University
Co-authored papers 5
Stanford University
Co-authored papers 5
MedStar Georgetown University Hospital
Co-authored papers 5
Princess Margaret Hospital, University of Toronto
Co-authored papers 4
University of California los angeles
Co-authored papers 4
Mount Sinai Hospital
Co-authored papers 4
Southwest Hospital, Army Medical University
Co-authored papers 4
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 3
University of California los angeles
Co-authored papers 3
University of California los angeles
Co-authored papers 3
MSC National Research Institute of Oncology Gliwice Branch
Co-authored papers 3
Tulane University School of Medicine
Co-authored papers 3
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Co-authored papers 3
university of california los angeles Medical Center
Co-authored papers 3
University of California davis
Co-authored papers 2
University of California los angeles
Co-authored papers 2
Maria Sklodowska-Curie National Research and Institute of Oncology
Co-authored papers 2
MSC National Research Institute of Oncology Gliwice Branch
Co-authored papers 2
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Co-authored papers 2
David Geffen School of Medicine at university of california los angeles
Co-authored papers 2
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2